AbbVie reports positive topline results from its Phase 3 UP-AA trial, showing upadacitinib (RINVOQ) significantly improved scalp hair coverage in patients with severe alopecia areata.
AstraZeneca has announced a landmark $50 billion investment in the United States through 2030, a strategic initiative designed to significantly enhance America’s leadership in pharmaceutical innovation.
Johnson & Johnson announced robust second-quarter 2025 financial results, surpassing analyst expectations and raising its full-year guidance. The healthcare giant reported a significant 5.8% increase in sales to $23.7 billion, driven by strong performances in its Innovative Medicine and MedTech segments.
The global biosimilars market is set for significant expansion in 2025, projected to reach between USD 21.95 billion and USD 42.53 billion.
Eyestem’s new cell therapy for Dry AMD, showing promising safety and vision improvement in Phase 1 trials. A new hope for treating geographic atrophy.
The first stage of mitosis and meiosis, two crucial cellular division processes that support an organism’s growth, repair, and reproduction, is known as prophase.The specifics [Read More…]
Compared to existing CAR T treatments, the off-the-shelf experimental therapeutic CTX112TM may allow for quicker patient access.
All nine subjects of phase 1 injected without any serious adverse events.
AFib affects around 8 million Europeans over the age of 65, and this figure is anticipated to grow over the next 30 years.
The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
